Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-30T22:25:50.319Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacoeconomic evaluations on anti psychotics in schizophrenia: a review of the Italian studies

Published online by Cambridge University Press:  18 May 2011

Michela Cerzani ,
Corrado Barbui  and
Livio Garattini
Michela Cerzani
Affiliation:
CESAV, Villa Camozzi, Via Camozzi 3, 24020 Ranica, Bergamo (Italy) Fax: +39-035-453.5372 E-mail: [email protected]
Corrado Barbui
Affiliation:
Dipartimento di Medicina e Sanità Pubblica, Sezione di Psichiatria e Psicologia Clinica, Università di Verona, Policlinico G.B. Rossi, P.le L.A. Scuro 10, 37134 Verona (Italy) Fax: +39-045-585.871 E-mail: [email protected]
Livio Garattini
Affiliation:
CESAV, Villa Camozzi, Via Camozzi 3, 24020 Ranica, Bergamo (Italy) Fax: +39-035-453.5372 E-mail: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Information
Epidemiology and Psychiatric Sciences , Volume 15 , Issue 2 , June 2006 , pp. 153 - 160
Copyright
Copyright © Cambridge University Press 2006

References

BIBLIOGRAFIA

Davis, J.M., Chen, N. & Glick, I.D. (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60, 553–564.CrossRefGoogle ScholarPubMed
De Compadri, P., Cornago, D. & Gonzalez, N. (2004). Il progetto europeo EURONHEED: un'ulteriore opportunità di sviluppo della farmacoeconomia? Economia & Politica del Farmaco 1(3), 30–33.Google Scholar
Garattini, L., Li Bassi, L., Ghislandi, S., Bon, A. & De Compadri, P. (2004). Gli studi di farmacoeconomia in Italia: una rassegna della letteratura esistente. Economia & Politica del Farmaco 1(1). 28–37.Google Scholar
Geddes, J., Freemantle, N., Harrison, P. & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medica/Journal 321, 1371–1376.CrossRefGoogle ScholarPubMed
Krimsky, S. (1999). Conflict of interest and cost-effectiveness analysis. Journal of American Medical Association 282(15), 1474–1475.CrossRefGoogle ScholarPubMed
Leucht, S., Wahlbeck, K., Hamann, J. & Kissling, W. (2003). New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361, 1581–1589.CrossRefGoogle ScholarPubMed
Magliano, L., Marasco, C., Fiorillo, A., Malangone, C., Guarnen, M., Maj, M. & Working Group of the Italian National Study on Families of Persons with Schizophrenia (2002). The impact of professional and social network support on the burden of families of patients with schizophrenia in Italy. Acta Psychiatrica Scandinavica 106 (4), 291–298.CrossRefGoogle ScholarPubMed
Mantovani, L., Berto, P., D'Ausilio, A. & Heeg, B. (2004). Costi ed effetti di Risperidone Long Ancting (RLA) rispetto ad antipsicotici atipici nel trattamento dei soggetti schizofrenici in Italia. Farmacoeconomia e Percorsi Terapeutici 5(1), 5–11.Google Scholar
Mapelli, V., Bezzi, R., Erlicher, A., Lora, A. & Miragoli, P. (2004). Costi ed efficacia della cura della schizofrenia con antipsicotici tipici e atipici. PharmacoEconomics Italian Research Articles 5(2). 15–30.CrossRefGoogle Scholar
Morgan, S., Barer, M. & Evans, R. (2000). Health economists meet the fourth tempter: drug dependency and scientific discourse. Health Economics 9, 659–667.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
Mullen, J., Reinstein, M., Bari, M & al. (1999). Quetiapine and risperidone in outpatients with psychotic disorders: results of the Quest trial. Poster presentato all' International Congress on Schizophrenia Research Biennal Meeting. Santa Fé, New Mexico, April 17–21.Google Scholar
Percudani, M. & Barbui, C. (2003). Cost and outcomes implications of using typical and atypical antipsychotic in ordinary practice in Italy. Journal Clinical Psychiatry 64(11), 1293–1299.CrossRefGoogle ScholarPubMed
Ravasio, R., Arrighi, E., Bitetto, A., Linciano, D., Lora, A., Sacchi, M. & Voltini, A. (2003). Risperidone vs olanzapina: un confronto di costo e di risultato nel trattamento ospedaliero della schizofrenia (Studio RODOS). PharmacoEconomics Italian Research Articles 5(2), 81–94.CrossRefGoogle Scholar
Rennte, D. & Luft, H. (2000). Pharmacoeconomic analysis: making them transparent, making them credible. Journal of American Medical Association 283 (16), 2158–2160.CrossRefGoogle Scholar
Rossi, I. & Guidi, L. (2001). Valutazione dei costi di trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici di un DMS italiano. Farmacoeconomia e Percorsi Terapeutici 2(4), 217–222.Google Scholar
Srisurapanont, M. & Maneeton, N. (1999). Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomised, placebo-controlled trials. Journal Medical Association of Thailand 82(4), 341–346.Google Scholar
Tarricone, R. (2001). Valutazione di convenienza economica comparata tra quetiapina e risperidone nel trattamento della schizofrenia. PharmacoEconomics Italian Research Articles 3(1), 27–36.CrossRefGoogle Scholar
Tarricone, R., Gerzeli, S., Montanelli, R., Frattura, L., Percudani, M. & Racagni, G. (2000). Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Health Policy 51, 1–18.CrossRefGoogle ScholarPubMed